Phase I trial of the novel taxane BMS-184476 administered in combination with carboplatin every 21 days

The aim of the study was to determine the maximum-tolerated dose and dose-limiting toxicities for BMS-184476, in combination with carboplatin, in patients with advanced solid tumours and to describe any preliminary antitumour activity associated with this regimen. Patients received combination thera...

Descripción completa

Detalles Bibliográficos
Autores principales: Bilenker, J H, Stevenson, J P, Gallagher, M L, Vaughn, D, Cohen, M B, O'Dwyer, P J
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2004
Materias:
Clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/
https://www.ncbi.nlm.nih.gov/pubmed/15213727
http://dx.doi.org/10.1038/sj.bjc.6601885

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2409820/
https://www.ncbi.nlm.nih.gov/pubmed/15213727
http://dx.doi.org/10.1038/sj.bjc.6601885

Ejemplares similares